EUVIMEDEUVIMED entdecken
Crossref

Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort

Stefanie Hegenberg, Tobias Germing, Elena Schlageter, Ira Ekmekciu, Jens Christmann, Andrea Tannapfel, Anke Reinacher-Schick

Oncology Research and Treatment · 2025

DOI: 10.1159/000543997 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Stefanie Hegenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Biomarkers, Tumor. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy and precision oncology treatment options may improve patient outcomes. Next-generation sequencing (NGS) is an established tool that enables multigene panel analysis.

Methods

This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021.

Results

A targetable lesion was detected in 15.6% of patients. BRCA1/2 mutations were identified in 16 patients, of whom 13 had germline mutations; 8 of these patients received olaparib. In 41.4% of patients, homologous recombination repair genes were affected. Two cases of ATP1B1-NRG1 fusions and seven cases of dMMR tumors were found, leading to individualized treatment. KRAS mutations were present in 70.3%, and TP53 mutations were present in 63.3%. A total of 80.5% of patients received platinum-based chemotherapy, predominantly FOLFIRINOX.

Conclusion

The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalBiomarkers, TumorHumansFemaleMiddle AgedMaleAgedHigh-Throughput Nucleotide SequencingAntineoplastic Combined Chemotherapy ProtocolsAdultProto-Oncogene Proteins p21(ras)Aged, 80 and overPrecision MedicineLeucovorinMutationCohort StudiesIrinotecanGerm-Line MutationOxaliplatinBRCA2 ProteinBRCA1 ProteinFluorouracil

Stichwörter der Autor:innen

BRCAFluorouracil, leucovorin, irinotecan, and oxaliplatinNext-generation sequencingPancreatic cancerTarget therapy

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanfolfirinoxBiomarkers, TumorLeucovorinIrinotecanOxaliplatinBRCA2 ProteinBRCA1 ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
  • Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.

Zitieren

APA

Hegenberg, S., Germing, T., Schlageter, E., Ekmekciu, I., Christmann, J., Tannapfel, A., & Reinacher-Schick, A. (2025). Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort. Oncology Research and Treatment. https://doi.org/10.1159/000543997

Vancouver

Hegenberg S, Germing T, Schlageter E, Ekmekciu I, Christmann J, Tannapfel A, et al. Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort. Oncology Research and Treatment. 2025. doi:10.1159/000543997

BibTeX
@article{Hegenberg2025,
  author = {Hegenberg, Stefanie and Germing, Tobias and Schlageter, Elena and Ekmekciu, Ira and Christmann, Jens and Tannapfel, Andrea and Reinacher-Schick, Anke},
  title = {Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort},
  journal = {Oncology Research and Treatment},
  year = {2025},
  doi = {10.1159/000543997}
}
Kostenlos starten →